Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species

Current Opinion in Infectious Diseases

Volumn 21, Issue 4, 2008, Pages 415-420

  Blair, Janis E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Coccidioidomycosis; Fungal infections; Organ transplantation; Prophylaxis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; ITRACONAZOLE; NIKKOMYCIN Z; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

CASE MANAGEMENT; CHEMOPROPHYLAXIS; COCCIDIOIDES; COCCIDIOIDOMYCOSIS; DIABETES MELLITUS; DRUG CHOICE; FUNGUS TRANSMISSION; GRAFT RECIPIENT; HEMODIALYSIS; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; ORGAN TRANSPLANTATION; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; RELAPSE; REVIEW; RISK FACTOR; ENDEMIC DISEASE; TRANSPLANTATION; UNITED STATES;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; COCCIDIOIDOMYCOSIS; ENDEMIC DISEASES; HUMANS; SOUTHWESTERN UNITED STATES; TRANSPLANTS;

EID: 49049108204     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283073828     Document Type: Review

References (40)

1. Cox RA, Magee DM. Coccidioidomycosis: host response and vaccine development. Clin Microbiol Rev 2004; 17:804-839.
2. Ampel NM. The complex immunology of human coccidioidomycosis. Ann N Y Acad Sci 2007; 1111:245-258. A well organized review clearly detailing the complicated immunologic fight against coccidioidomycosis. Includes information about the clinical expression of coccidioidomycosis and its relationship to immunity.
3. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351:2715-2729.
4. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol 2007; 45:305-320. This well organized review of common and uncommonfungal infections after allograft transplantation provides an updated summary of presentation, prophylaxis and treatment of Candida sp., Aspergillus sp., Cryptococcus sp., Fusarium sp., agents of zygomycosis, and other molds as well as endemic fungi.
5. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601-2614. A well organized, updated overview of common infections throughout the life span of transplant recipients. Recent changes in immunosuppression and prophylaxis are addressed as they relate to infections.
6. Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001; 33:1536-1544.
7. Blair JE. Coccidioidomycosis in liver transplantation. Liver Transpl 2006; 12:31-39.
8. Blair JE, Balan V, Douglas DD, Hentz JG. Incidence and prevalence of coccidioidomycosis in patients with end-stage liver disease. Liver Transpl 2003; 9:843-850.
9. Sachdev MS, Blair JE, Mulligan DC, Kusne S. Coccidioidomycosis masked by symptoms of end-stage liver disease in transplant candidates. Transpl Infect Dis 2007; 9:153-155. Case reports of coccidioidomycosis in patients with cirrhosis. Points out that coccidioidal symptoms may be overlooked or mistaken as symptoms of cirrhosis and portal hypertension.
10. Cohen IM, Galgiani JN, Potter D, Ogden DA. Coccidioidomycosis in renal replacement therapy. Arch Intern Med 1982; 142:489-494.
11. Laniado-Laborin R. Expanding understanding of epidemiology of coccidioidomycosis in the Western hemisphere. Ann N Y Acad Sci 2007; 1111:19-34. A summary of the risk factors for acquisition and manifestation of coccidioidomycosis and of trends in the incidence of coccidioidomycosis in the endemic and nonendemic regions of the USA as well as of Central America and South America.
12. Santelli AC, Blair JE, Roust LR. Coccidioidomycosis in patients with diabetes mellitus. Am J Med 2006; 119:964-969.
13. Blair JE, Kusne S, Carey EJ, Heilman RL. The prevention of recrudescent coccidioidomycosis after solid organ transplantation. Transplantation 2007; 83:1182-1187. A summary of one transplant center's experience with controlling coccidioidomycosis (acquired before transplantation) after kidney, pancreas, or liver transplantation in 47 patients. In the 44 patients with controlled coccidioidomycosis, no recrudescent infection occurred unless antifungals were discontinued. Two of the three patients with less than optimal coccidioidal control at transplantation did well.
14. Braddy CM, Heilman RL, Blair JE. Coccidioidomycosis after renal transplantation in an endemic area. Am J Transplant 2006; 6:340-345.
15. Rosenstein NE, Emery KW, Werner SB, et al. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996. Clin Infect Dis 2001; 32:708-715.
16. Miller MB, Hendren R, Gilligan PH. Posttransplantation disseminated coccidioidomycosis acquired from donor lungs. J Clin Microbiol 2004; 42:2347-2349.
17. Tripathy U, Yung GL, Kriett JM, et al. Donor transfer of pulmonary coccidioidomycosis in lung transplantation. Ann Thorac Surg 2002; 73:306-308.
18. Wright PW, Pappagianis D, Wilson M, et al. Donor-related coccidioidomycosis in organ transplant recipients. Clin Infect Dis 2003; 37:1265-1269.
19. Blair JE, Mulligan DC. Coccidioidomycosis in healthy persons evaluated for liver or kidney donation. Transpl Infect Dis 2007; 9:78-82. Details the serologic results of screening organ donors, and notes the lack of coccidioidomycosis in organ recipients without specific anticoccidioiodal prophylaxis.
20. Blair JE, Coakley B, Santelli AC, et al. Serologic testing for symptomatic coccidioidomycosis in immunocompetent and immunosuppressed hosts. Mycopathologia 2006; 162:317-324.
21. Blair JE. Coccidioidomycosis in patients who have undergone transplantation. Ann N Y Acad Sci 2007; 1111:365-376. Updates the coccidioidomycosis-related findings in all transplant programmes (kidney, pancreas, liver, blood, and bone marrow) at a single institution in the endemic area.
22. Murali HR, Josephs KA, Wijdicks EF. Guillain-Barrésyndrome in an immunocompromised patient and coccidioidomycosis infection. Rev Neurol Dis 2006; 3:82-84.
23. Blair JE. Coccidioidal pneumonia, arthritis, and soft-tissue infection after kidney transplantation. Transpl Infect Dis 2004; 6:74-76.
24. Kotton CN, Marconi VC, Fishman JA, et al. Coccidioidal meningitis after liver transplantation in a nonendemic region: a case report. Transplantation 2006; 81:132-134.
25. Takei H, Goodman JC, Powell SZ. Leg weakness after liver transplant. Brain Pathol 2007; 17:470-471; 473-475. A case study of coccidioidal meningitis and coccidioidoma after liver transplantation.
26. Rempe S, Sachdev MS, Bhakta R, et al. Coccidioides immitis fungemia: clinical features and survival in 33 adult patients. Heart Lung 2007; 36:64-71. Although not transplant specific, this is a summary of the literature as it relates to a positive fungal blood culture for Coccidioides sp. Such fungemia is associated with septic shock and high mortality.
27. Binnicker MJ, Buckwalter SP, Eisberner JJ, et al. Detection of Coccidioides species in clinical specimens by real-time PCR. J Clin Microbiol 2007; 45:173-178. Study of a novel method of detection using polymerase chain reaction to detect Coccidioides sp. in clinical specimens.
28. Assi MA, Binnicker MJ, Wengenack NL, et al. Disseminated coccidioidomycosis in a liver transplant recipient with negative serology: use of polymerase chain reaction. Liver Transpl 2006; 12:1290-1292.
29. th International Conference on Coccidioidomycosis; August 24-27 1994; Stanford, CA. Edited by Einstein H, Catanzaro A (editors). Bethesda (MD): National Foundation for Infectious Diseases Press; 1996. pp. 248-254.
30. Galgiani JN, Ampel NM, Blair JE, et al., Infectious Diseases Society of America. Coccidioidomycosis. Clin Infect Dis 2005; 41:1217-1223.
31. Anstead GM, Corcoran G, Lewis J, et al. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005; 40:1770-1776.
32. Antony SJ, Jurczyk P, Brumble L. Successful use of combination antifungal therapy in the treatment of coccidioides meningitis. J Natl Med Assoc 2006; 98:940-942.
33. Park DW, Sohn JW, Cheong HJ, et al. Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole. BMC Infect Dis 2006; 6:26.
34. Stevens DA, Rendon A, Gaona-Flores V, et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007; 132:952-958. Open-label trial of posaconazole for salvage treatment of refractory coccidioidomycosis. Eleven of 15 patients who were previously refractory to amphotericin B with or without another azole had a complete or partial response to treatment.
35. Crum-Cianflone NF. Voriconazole in combination with amphotericin B for salvage therapy of coccidioidomycosis: case report and review of the literature. Infect Dis Clin Pract 2007; 15:265-268. Case study on the use of voriconazole and amphotericin B for salvage treatment of coccidioidal infection. Not specific to transplantation.
36. Gonzalez GM, Gonzalez G, Najvar LK, Graybill JR. Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model. J Antimicrob Chemother 2007; 60:1341-1346. In-vivo study of the use of caspofungin in a mouse model of coccidioidal infection with evidence of a biological basis that caspofungin may possibly have a future role in treatment.
37. Holt CD, Winston DJ, Kubak B, et al. Coccidioidomycosis in liver transplant patients. Clin Infect Dis 1997; 24:216-221.
38. Galgiani JN. Coccidioidomycosis: changing perceptions and creating opportunities for its control. Ann N Y Acad Sci 2007; 1111:1-18. This is a brief review of the history of the treatment of coccidioidomycosis, in which the author speculates on how the infection came to be viewed as a low-priority agent for treatment. The author calls for a paradigm change with regard to the treatment approach to this fungal infection. Among other antifungal medications, the novel antifungal agent nikkomycin Z is reviewed.
39. Warnock DW. Coccidioides species as potential agents of bioterrorism. Future Microbiol 2007; 2:277-283. Delineates the details of Coccidioides sp. and its place as a potential agent of bioterrorism.
40. Hector R, Rutherford GW. The public health need and present status of a vaccine for the prevention of coccidioidomycosis. Ann N Y Acad Sci 2007; 1111:259-268. This is a brief review of efforts to develop a coccidioidal vaccine and the need to advance it as a viable prevention tool in the future.